Weekly cisplatin (40 mg/m2) versus three-weekly (100mg/m2) cisplatin delivered concurrently with radiotherapy in high risk head and neck cancer patients

CONCURRENT CHEMO-RADIOTHERAPY OF WEEKLY PACLITAXEL VERSUS WEEKLY CARBOPLATIN IN LOCALLY ADVANCED HEAD AND NECK CARCINOMAS UNFIT FOR CISPLATIN

NEOADJUVANT CHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIATION FOR LOCALLY ADVANCED HEAD AND NECK CANCERS

Induction chemotherapy followed by chemoradiation versus upfront chemoradiation in locally advanced head and neck cancers A prospective randomized study

Induction Chemotherapy Versus Upfront Chemoradiation for Locoregionally Advanced of Head and Neck Cancer

COMPARISON BETWEEN CONCOMITANT CHEMO-RADIOTHERAPY WITH CISPLATIN VERSUS INDUCTION CHEMOTHERAPY FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY WITH CISPLATIN AND ETOPOSIDE REGIMEN IN C

The Outcomes of Concomitant Hypofractionated Simultaneous Integrated Boost Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin monotherapy for Newly Diagnosed Local

Accelerated Fractionation Radiotherapy and Chemotherapy Might Improve Loco-Regional Control of Head and Neck Squamous Cell Carcinoma

A Retrospective Study of Reirradiation for Patients with Locoregional Recurrent Head and Neck Cancer: A Single-Institution Experience

Three-Dimensional Conformal Radiotherapy with Concomitant Boost and Weekly Cisplatin in Muscle-Invasive Transitional Cell Bladder Carcinoma